alexa Abstract | Xolair: A New Monoclonal Drug Anti-IgE Antibody for the Treatment of Allergic Asthma

Biomedical Research
Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)


Xolair is a monoclonal antibody that binds the Cε3 domain of IgEs, inducing a conforma-tional change of the immunoglobulin, a concealment of FcεRI and FcεRII receptors binding sites, thus precluding binding by IgEs and therefore stopping the release of inflammation mediators. Xolair is indicated as add-on therapy to improve/control asthma in adult and adolescent patients (12 years of age and above) suffering from severe persistent allergic asthma. The aim of our work was to evaluate the Xolair efficacy in the asthma treatment. Six patients (4 men and 2 women aged 30 to 60 years) were selected for the treatment with Xolair. Previously, they were treated with high doses of long-acting β2-agonists and inhaled corticosteroids, but they were not able to control their illness despite the assumption of such drugs. Xolair was administered for 32 weeks in addition to the traditional asthma therapy. Xolair dosage was calculated according to their weight and their IgE levels (IU/ml). The the-rapeutic response was evaluated according to the GETE (Global Evaluation of Treatment Effectiveness) scale. The persistence of the response was defined, instead, by the number of patients continuing to respond positively to the treatment between the 16th and the 32nd week. 4 of 6 patients concluded the study. Patient number 2, in fact, had a body weight higher than 150 kg, so it was impossible to establish the necessary drug dosage. Patient number 6, instead, still had too high IgE values at his fourth checkup. Patient number 1 was fit in the efficacy level 2 (Good) at the 16th week, while at the 32nd week, he was in the level 1 (Excellent). Patient number 3 was at an efficacy level 1 yet from the 16th week, and that level was confirmed at the 32nd. In patient number 4, as well in that number 1, an increase of treatment efficacy was proved with a passage from level 2 to level 1. Finally, for the patient number 5, the efficacy level was Good both at the 16th and at the 32nd week (level 2). The re-sults obtained were positive for all patients and not only the persistence of a therapeutic re-sponse was confirmed, but in some cases there was an improvement of efficacy. Therefore, we can conclude that Xolair, administrated as an additional therapy, strongly improved the severe persistent IgE-mediated asthma. The anti-IgE Xolair treatment reduces the asthma frequency, also, it improved the patient life quality, by inducing positive effects on symp-toms and pulmonary function.

To read the full article Peer-reviewed Article PDF image | Peer-reviewed Full Article image

Author(s): Monica Di Domenico Mario Polverino Concetta De Rosa Vilma Ricci Angelica Bisogno Anna Capasso


Asthma, allergy, inflammation, Ig-E

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version